Atopic dermatitis

Abrocitinib, an oral Janus kinase (JAK) 1 inhibitor, provides an efficacious alternative for adults nonresponsive to other systemic therapies. Atopic Dermatitis (AD) affects 1% to 3% of adults and 15% to 20% of children globally. The use of emollients and avoidance of triggers is advised for all patients.  Topical treatments, such as topical corticosteroids or...

Early antibiotic exposure, particularly during weeks 2, 3, and 4, may reduce the development of AD later in life. Atopic dermatitis (AD) is a chronic, inflammatory skin disease that affects about 11% of children in the United States. Most cases manifest during infancy and early childhood. The findings of this study were published in JAAD...

In everyday practice, upadacitinib can be a successful treatment for patients with atopic dermatitis and concurrent hand eczema. These findings are reported in a multicenter observational cohort study published in Contact Dermatitis that aims to assess the 16-week efficacy and safety of upadacitinib for atopic dermatitis (AE) and hand eczema (HE) in AD patients. Upadacitinib...

Upadacitinib treatment for atopic dermatitis patients has been associated with acne. However, a phase 3 randomized control trial has revealed that the severity of this adverse event is typically mild-to-moderate, and can be effectively managed through the use of topical therapies or left untreated. These findings are reported in the Journal of the American Academy...

Food allergy is common in moderate-to-severe and early-onset atopic dermatitis. Accurate detection of food allergies is essential for increasing treatment efficacy and preventing unnecessary diets. Atopic dermatitis (AD) is a chronic, recurring, inflammatory skin condition that affects 2 to 20% of the population. Nearly 50% of cases in children start in the first year of...

Wheatgrass and aronia extract combination offers anti-inflammatory and antioxidant benefits in inflammatory skin disorders such as atopic dermatitis and could be a natural therapeutic alternative. Atopic dermatitis (AD), characterized by dry and sensitive skin, pruritus, and eczema, is an inflammatory skin disease typically characterized by cycles of remission and relapse. Approximately 20% of children and...

Patients with immunodeficiencies and antibody deficiencies typically have atopic symptoms, which should be addressed to avoid worsening of the condition. Primary immunodeficiency diseases (PIDs) are a heterogeneous set of more than 300 inherited immunity abnormalities caused by variations in genes encoding functional proteins of human immune cells. The estimated incidence of symptomatic PIDs is 1...

Dupilumab therapy improves 16-week efficacy parameters in adults diagnosed with moderate-to-severe intensity AD, regardless of Japanese ethnicity. Atopic dermatitis (AD) is a systemic inflammatory condition characterized by eczematous lesions with intense pruritus. Dupilumab is a human-derived monoclonal antibody that blocks the shared interleukin (IL)-4 and IL-13 receptors, thereby inhibiting their signaling. This randomized controlled trial,...

Children and adolescents with atopic dermatitis demonstrate significant improvement in SCORing Atopic Dermatitis (SCORAD) outcomes following dupilumab ± topical corticosteroids administration. Atopic dermatitis (AD) is amongst the most prevalent inflammatory dermatoses in children. Moderate-to-severe AD is characterized by increased health burden and poor quality of life (QoL). Affected individuals are more likely to be diagnosed...